Somatostatin receptor-based cancer therapy
Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant.
1 . A constitutively active somatostatin receptor type 2 (SSTR2) mutant, wherein the mutant is a C-terminal deletion mutant of a human somatostatin receptor, wherein mutant is SSTR2 delta 340 mutant with the sequence of amino acids 1-340 of SEQ ID NO:6.
2 . A therapeutic composition comprising the mutant of claim 1 and a pharmaceutically acceptable carrier.
3 . A nucleic acid molecule comprising a constitutively active somatostatin receptor (SSTR2) mutant of a human somatostatin receptor, having a nucleotide sequence that encodes the amino acids 1-340 of SEQ ID NO: 6.
4 . A therapeutic composition comprising the nucleic acid of claim 3 , and a pharmaceutically acceptable carrier.
5 . An expression construct comprising the nucleic acid molecule of claim 3 .
6 . A therapeutic composition comprising the expression construct of claim 5 , and a pharmaceutically acceptable carrier.
7 . The expression construct of claim 5 , wherein the nucleic acid further comprises a second coding sequence.
8 . The expression construct of claim 7 , wherein the second coding sequence is a protein tag gene, a reporter gene, a therapeutic gene, a signaling sequence, or a trafficking sequence.